Parallel Bio reimagined the entire drug discovery process from the ground up - creating a system that charts the map of human biology. A system that’s population-scale, perturbable, and fully human - with the power to reveal the biological landscape of any disease.
Parallel Biosystems, Inc. owns and operates the site. Its privacy policy describes how it treats personal information belonging to job applicants, customers, and the general public.
Parallel Bio raises $21 million in Series A funding led by AIX Ventures to expand its human-first drug discovery platform. The company says the financing will support expansion of its platform for human-first drug discovery, with AIX Ventures leading the Series A round.
Parallel Bio appoints Dwight Morrow as vice president and head of platform, and adds Darrell Irvine and Nima Aghaeepour as scientific advisors. The company describes the additions as coming from GSK, MIT, and Stanford.
Parallel Bio secures $4.3 million in seed funding led by Refactor Capital to develop its human immune system platform. The funding is intended to accelerate drug discovery through a human immune system in a dish.